Medicines planning
50 results
Applied filters
New Product Evaluations
14 November 2024A list of new product evaluations that are freely available to NHS staff.
Using our annual medicines planning publication, Prescribing Outlook
28 October 2024Users should be aware of the constraints and assumptions in creating Prescribing Outlook, as well as their responsibilities for use.
Good governance when implementing ustekinumab biosimilar
2 August 2024Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring, and pharmacovigilance.
The licence and supporting evidence for ustekinumab biosimilars
2 August 2024Ustekinumab biosimilars (Pyzchiva, Steqeyma, Uzpruvo, Wezenla) are licensed. Learn about indications, formulations, supporting evidence and differences.
Preparing to use ustekinumab biosimilar
16 July 2024Introducing biosimilar ustekinumab needs planning. Work with the multidisciplinary team to ensure familiarity with the area and develop an implementation plan.
Good governance when implementing eculizumab biosimilar
6 March 2024Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring, and pharmacovigilance.
The licence and supporting evidence for eculizumab biosimilars
6 March 2024Two licensed eculizumab biosimilars are available: Bekemv and Epysqli. Learn about the licensed indications, supporting evidence and key differences.
Preparing to use eculizumab biosimilar
6 March 2024Introducing biosimilar eculizumab needs planning. Work with the multidisciplinary team to ensure familiarity with the area and develop an implementation plan.
Good governance when implementing tocilizumab biosimilar
5 March 2024Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring, and pharmacovigilance.
The licence and supporting evidence for tocilizumab biosimilar
5 March 2024One licensed tocilizumab biosimilar is available: Tyenne. Learn about the licensed indications, supporting evidence and key differences.